Recombinant Human HLA class I histocompatibility antigen, A-3 alpha chain (HLA-A), partial

中文名稱：

人HLA-A重組蛋白
貨號：

CSB-YP356256HU
說明書：

MSDS Datasheet
規格：
來源：

Yeast
其他：

中文名稱：

人HLA-A重組蛋白
貨號：

CSB-EP356256HU
說明書：

MSDS Datasheet
規格：
來源：

E.coli
其他：

中文名稱：

人HLA-A重組蛋白
貨號：

CSB-EP356256HU-B
說明書：

MSDS Datasheet
規格：
來源：

E.coli
共軛：

Avi-tag Biotinylated
E. coli biotin ligase (BirA) is highly specific in covalently attaching biotin to the 15 amino acid AviTag peptide. This recombinant protein was biotinylated in vivo by AviTag-BirA technology, which method is BriA catalyzes amide linkage between the biotin and the specific lysine of the AviTag.
其他：

中文名稱：

人HLA-A重組蛋白
貨號：

CSB-BP356256HU
說明書：

MSDS Datasheet
規格：
來源：

Baculovirus
其他：

中文名稱：

人HLA-A重組蛋白
貨號：

CSB-MP356256HU
說明書：

MSDS Datasheet
規格：
來源：

Mammalian cell
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

純度：

>85% (SDS-PAGE)
基因名：

HLA-A
Uniprot No.：

P04439
別名：

1A03_HUMAN; A-1 alpha chain; A-3 alpha chain; antigen presenting molecule; AS; D6S204; HLA class I histocompatibility antigen; HLA-A; HLA-A heavy chain; HLA-JY3; HLAA; HLAB; HLC-C; leukocyte antigen class I-A; MHC class I antigen ; MHC class I antigen A*3; PSORS1; SPDA1
種屬：

Homo sapiens (Human)
蛋白長度：

Partial
蛋白標簽：

Tag?type?will?be?determined?during?the?manufacturing?process.

The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
產品提供形式：

Lyophilized powder Warning: in_array() expects parameter 2 to be array, null given in /www/web/cusabio_cn/public_html/caches/caches_template/default/content/show_product_protein.php on line 662
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
復溶：

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
儲存條件：

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
保質期：

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
貨期：

Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
注意事項：

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet ：

Please contact us to get it.

產品評價

靶點詳情

功能：

Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumor-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-A-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells. May also present self-peptides derived from the signal sequence of secreted or membrane proteins, although T cells specific for these peptides are usually inactivated to prevent autoreactivity. Both the peptide and the MHC molecule are recognized by TCR, the peptide is responsible for the fine specificity of antigen recognition and MHC residues account for the MHC restriction of T cells. Typically presents intracellular peptide antigens of 8 to 13 amino acids that arise from cytosolic proteolysis via IFNG-induced immunoproteasome or via endopeptidase IDE/insulin-degrading enzyme. Can bind different peptides containing allele-specific binding motifs, which are mainly defined by anchor residues at position 2 and 9.; Allele A*01:01: Presents a restricted peptide repertoire including viral epitopes derived from IAV NP/nucleoprotein (CTELKLSDY), IAV PB1/polymerase basic protein 1 (VSDGGPNLY), HAdV-11 capsid L3/hexon protein (LTDLGQNLLY), SARS-CoV-2 3a/ORF3a (FTSDYYQLY) as well as tumor peptide antigens including MAGE1 (EADPTGHSY), MAGEA3 (EVDPIGHLY) and WT1 (TSEKRPFMCAY), all having in common a canonical motif with a negatively charged Asp or Glu residue at position 3 and a Tyr anchor residue at the C-terminus. A number of HLA-A*01:01-restricted peptides carry a post-translational modification with oxidation and N-terminal acetylation being the most frequent. Fails to present highly immunogenic peptides from the EBV latent antigens.; Allele A*02:01: A major allele in human populations, presents immunodominant viral epitopes derived from IAV M/matrix protein 1 (GILGFVFTL), HIV-1 env (TLTSCNTSV), HIV-1 gag-pol (ILKEPVHGV), HTLV-1 Tax (LLFGYPVYV), HBV C/core antigen (FLPSDFFPS), HCMV UL83/pp65 (NLVPMVATV) as well as tumor peptide antigens including MAGEA4 (GVYDGREHTV), WT1 (RMFPNAPYL) and CTAG1A/NY-ESO-1 (SLLMWITQC), all having in common hydrophobic amino acids at position 2 and at the C-terminal anchors.; Allele A*03:01: Presents viral epitopes derived from IAV NP (ILRGSVAHK), HIV-1 nef (QVPLRPMTYK), HIV-1 gag-pol (AIFQSSMTK), SARS-CoV-2 N/nucleoprotein (KTFPPTEPK) as well as tumor peptide antigens including PMEL (LIYRRRLMK), NODAL (HAYIQSLLK), TRP-2 (RMYNMVPFF), all having in common hydrophobic amino acids at position 2 and Lys or Arg anchor residues at the C-terminus. May also display spliced peptides resulting from the ligation of two separate proteasomal cleavage products that are not contiguous in the parental protein.; Allele A*11:01: Presents several immunodominant epitopes derived from HIV-1 gag-pol and HHV-4 EBNA4, containing the peptide motif with Val, Ile, Thr, Leu, Tyr or Phe at position 2 and Lys anchor residue at the C-terminus. Important in the control of HIV-1, EBV and HBV infections. Presents an immunodominant epitope derived from SARS-CoV-2 N/nucleoprotein (KTFPPTEPK).; Allele A*23:01: Interacts with natural killer (NK) cell receptor KIR3DL1 and may contribute to functional maturation of NK cells and self-nonself discrimination during innate immune response.; Allele A*24:02: Presents viral epitopes derived from HIV-1 nef (RYPLTFGWCF), EBV lytic- and latent-cycle antigens BRLF1 (TYPVLEEMF), BMLF1 (DYNFVKQLF) and LMP2 (IYVLVMLVL), SARS-CoV nucleocapsid/N (QFKDNVILL), as well as tumor peptide antigens including PRAME (LYVDSLFFL), all sharing a common signature motif, namely an aromatic residue Tyr or Phe at position 2 and a nonhydrophobic anchor residue Phe, Leu or Iso at the C-terminus. Interacts with natural killer (NK) cell receptor KIR3DL1 and may contribute to functional maturation of NK cells and self-nonself discrimination during innate immune response.; Allele A*26:01: Presents several epitopes derived from HIV-1 gag-pol (EVIPMFSAL, ETKLGKAGY) and env (LVSDGGPNLY), carrying as anchor residues preferentially Glu at position 1, Val or Thr at position 2 and Tyr at the C-terminus.; Allele A*29:02: Presents peptides having a common motif, namely a Glu residue at position 2 and Tyr or Leu anchor residues at the C-terminus.; Allele A*32:01: Interacts with natural killer (NK) cell receptor KIR3DL1 and may contribute to functional maturation of NK cells and self-nonself discrimination during innate immune response.; Allele A*68:01: Presents viral epitopes derived from IAV NP (KTGGPIYKR) and HIV-1 tat (ITKGLGISYGR), having a common signature motif namely, Val or Thr at position 2 and positively charged residues Arg or Lys at the C-terminal anchor.; Allele A*74:01: Presents immunodominant HIV-1 epitopes derived from gag-pol (GQMVHQAISPR, QIYPGIKVR) and rev (RQIHSISER), carrying an aliphatic residue at position 2 and Arg anchor residue at the C-terminus. May contribute to viral load control in chronic HIV-1 infection.
基因功能參考文獻：
1. HLA-A*24, the SLC30A8 T allele and high BMI are associated with poor graft outcome in type 1 diabetics undergoing pancreatic islet transplantation. PMID: 29679103
2. These data suggest that HLA-A*02:07 might be a genetic risk factor for developing clarithromycin-related cutaneous adverse drug reactions in Han Chinese and serve as a useful biomarker for personalized medicine to prevent these adverse reactions PMID: 29575644
3. Allelic and haplotype diversity of HLA-A, HLA-B and HLA-DRB1 gene at high resolution in the Nanning Han population. PMID: 29908012
4. Results indicted that HLA-A*02 and HLA-DRB1 (*0407, *15 and *1501) polymorphisms might increase the risk of aplastic anemia (AA), while HLA-DRB1 (*0301, *04, *0406, *0802, *1301, *1302 and *14) were protective against AA. PMID: 28902578
5. The HLA-A*31:01 allele is associated with carbamazepine-DRESS syndrome in Tunisians. PMID: 29125944
6. HLA-A2 status was not identified as prognostic for benefit in a large advanced NSCLC population treated with platinum-based chemotherapy. PMID: 29191581
7. HLA-A*31:01 and HLA-B*15:02 alleles confer susceptibility to carbamazepine-induced severe cutaneous adverse reactions. PMID: 28884973
8. Furthermore, the KIR3DS1 + HLA-Bw4, KIR3DS1 + HLA-Bw4 (Iso80) , and KIR3DS1 + HLA-A Bw4 genotypes were significantly more common in recovered individuals than both healthy control and patient groups. PMID: 29032460
9. The association of the HLA-A*24:02, HLA-B*39:01 and HLA-B*39:06 alleles with type 1 diabetes is restricted to specific HLA-DR/HLA-DQ haplotypes in Finns. PMID: 28185422
10. in the Iranian population, HLA-A*68 confers susceptibility to Graves' disease PMID: 28919585
11. this study shows a significant protective function for HLA-A*30 gene against chronic renal failure development in Yemeni patients PMID: 28919587
12. The authors concluded that in the Chinese population, HLA-A*02:01 and DRB1*11:01 might be associated with the host capacity to clear hepatitis C virus independent of IL28B, which suggests that the innate and adaptive immune responses both play an important role in the control of hepatitis C virus. PMID: 27511600
13. These results suggest a detrimental role of HLA-A-Bw4 and HLA-C2 groups, which are associated with the development of chronic hepatitis B, and a protective role of KIR2DL3. PMID: 28211154
14. data showed that the presence of the HLA class II allele DQB1*03:02 was a correlate of immune protection against HIV infection, while the presence of the HLA class I allele A*02:01 was associated with being infected with HIV. PMID: 28218480
15. The difference in MS risk between the extremes was considerable; smokers carrying HLA-DRB1*15 and lacking HLA-A*02 had a 13-fold increased risk compared with never smokers without these genetic risk factors (OR 12.7, 95% CI 10.8-14.9). The risk of MS associated with HLA genotypes is strongly influenced by smoking status and vice versa. PMID: 28597127
16. in this exploratory analysis of tuberculosis and HLA allele frequencies in Dene and Cree cohorts HLA-A*03 and HLA-DQB1*05:03 were significantly associated with tuberculosis in Manitoba, Canada PMID: 28359736
17. A total of 39 HLA-A, 66 HLA-B and 47 HLA-DRB1 alleles were identified. PMID: 27511726
18. results demonstrate that HIV-1 Nef's inferior ability to downregulate MHC-B compared to that of MHC-A is conserved across primate lentiviruses and suggest that this property influences antiviral cellular immune responses. PMID: 29046444
19. Data (from studies using TCR-F50/GIL/HLA-A2) suggest there are multiple solutions to recognizing identical peptide-MHC ligand with sufficient affinity to elicit broad anti- influenza virus response protective against viral escape. (TCR-F50 = GIL-specific T-cell receptor, alpha-beta; HLA-A2 major histocompatibility complex class I A; GIL = immunodominant influenza A virus epitope from M1) [M1, matrix protein 1] PMID: 28931605
20. HLA-A1 allele frequencies were overrepresented and HLA-A2 allele frequencies were underrepresented in cases of EBV + PTLD compared with EBV - PTLD after SOT. EBV + PTLDs in HLA-A1 carriers developed primarily in already EBV-seropositive recipients, which suggests an impaired immunological control of the latent EBV infection in this subgroup. PMID: 27104753
21. In the present study, the HLA-A*31:01 allele was identified as a risk allele of lamotrigine-induced severe cutaneous adverse reactions in Koreans PMID: 28351624
22. Three new HLA class I alleles, HLA-A*02:620, HLA-B*27:150 and HLA-B*07:05:01:02, were described in the Spanish Caucasoid population PMID: 28383785
23. Data suggest that KH1 and HK2 domains of MEX3C bind with high affinity to MRE10, a 10-mer RNA (5prime-CAGAGUUUAG-3prime) containing an eight-nucleotide MEX3C recognition element motif (AGAGUUUA); 3prime-untranslated region of HLA-A2 mRNA contains such a high affinity binding site for KH domains of MEX3C. (MEX3C = mex-3 RNA binding family member C; HLA-A2 = HLA class I histocompatibility antigen, A-2 alpha chain) PMID: 28808060
24. this study shows that alpha3-deletion isoform of HLA-A11 plays role in the immune escape of HIV-1 PMID: 28784847
25. Data suggest that personalized peptide vaccine (PPV) with these nine CTL epitope peptides exhibit a good safety profile and positive immunological responses in HLA-A11+ or -A33+ cancer patients. PMID: 28178396
26. findings demonstrate that gliadins contain epitopes that elicit CD8+ T cell responses restricted by HLA class I A*0101 and B*0801 molecules PMID: 28148736
27. The haplotype HLA-A29/HLA-B44 was more common in primary immunodeficiency patients with fibromyalgia than in those without fibromyalgia. PMID: 28422000
28. Data suggest that only a small fraction of HLA-A*02:01- (HA)-binding ESO peptides are immunogenic, namely those that have high peptide-binding strength and peptide/HA complex stability. This study involved comparison of in silico-predicted and observed cytotoxic T-lymphocyte recognition of tumor antigen epitopes in melanoma patients and transgenic/knockout mice. (ESO = tumor antigen NY-ESO-1) PMID: 28536262
29. The safety, the overall survival (OS), and the immunological responses based on an ELISPOT assay were determined to assess differences in patients who were HLA-A24-positive [24(+)] and HLA-A24-negative [24(-)]. PMID: 28393243
30. Here we define the nature and extent of the variation in 3,489 HLA-A, 4,356 HLA-B and 3,111 HLA-C alleles. The common alleles of human populations comprise 42 core alleles, which represent all selected polymorphism, and recombinants that have assorted this polymorphism PMID: 28650991
31. It was shown that the HLA-A*34 allele is a risk factor for recurrent spontaneous abortion, while the HLA-A*24 and HLA-B*35 alleles are associated with protection, and no allele of the DRB1 locus was associated with recurrent spontaneous abortion PMID: 26312389
32. HLA-A alleles were not associated with predisposition to cutaneous leishmaniasis. PMID: 27301744
33. a significant level of epitope-specific T cells could be detected ex vivo in peripheral blood mononuclear cells from active TB patients by an HLA-A*11:01 dextramer carrying the peptide Rv3130c194-204. PMID: 27072810
34. In conclusion, our results confirm that the alleles HLA-A*02 and HLA-DRB1*07 are associated with the pathogenesis of vitiligo in the Brazilian population. We demonstrated that allele HLA-A*32 is associated with susceptibility to localized vitiligo. PMID: 26769539
35. HLA-A*24:02 is a common genetic risk factor for cutaneous adverse reactions induced by aromatic antiepileptic drugs in the southern Han Chinese and possibly other ethnic populations. PMID: 28476759
36. the results support that a regulated assembly of these noncanonical HLA-I conformers during the immune response may enhance the avidity of their interaction with LILRB1. PMID: 27109306
37. This study provided preliminary evidences supporting HLA-A2 in Caucasians contribute to the risk of Alzheimer's disease. PMID: 26979752
38. HLA-A*33:01 was associated with drug induced liver injury due to terbinafine and possibly fenofibrate and ticlopidine. PMID: 28043905
39. In Japanese individuals, combined genotyping for the associated variants thus far identified; that is, HLA-A*02:06, TLR3 rs3775296 T/T and Rec114 rs16957893 CG, may help to predict the risk for cold medicine-related Stevens-Johnson syndrome /TEN with severe ocular complications PMID: 28100913
40. identified an alternative binding conformation of naturally occurring peptides from Toxoplasma gondii bound by HLA-A*02:01 PMID: 28179428
41. This study demonstrated that an association between phenobarbital hypersensitivity and HLA-A*01:01 in Thai children. PMID: 27554620
42. This study demonstrated the influence of HLA-A polymorphisms on individuals to resist HIV-1 infection. PMID: 28224433
43. Data suggest that the immunoproteasome is involved in pathologic MHC class I (HLA-A, B, C, F and G) expression and maintenance of myokine production in Idiopathic inflammatory myopathies (IIMs). PMID: 27522114
44. The host HLA class I polymorphism might play an important role with the occurrence of Severe fever with thrombocytopenia syndrome (SFTS). A*30-B*13-DRB1*07 had negative correlation with the occurrence of SFTS; in contrast, haplotype A*02-B*15-DRB1*04 was positively correlated with SFTS. PMID: 27760141
45. data show that sequence similarity does not translate to structural mimicry of the paired epitopes in complexes with HLA-A*02:01, resulting in induction of distinct alphabetaTCR repertoires. PMID: 27645996
46. Results provide evidence that HLA-A*02:06/-B*39:01 haplotype is a potential genetic marker for tetanus antitoxin-induced exanthematous drug eruptions. PMID: 27749688
47. This study suggests that HLA-A*66:01 might be a marker for cmarkers only in those of European ancestry cold medicine Stevens-Johnson Syndrome with ocular complications in Brazilian individuals of Pardo and European ancestry and that HLA-B*44:03 and HLA-C*12:03 might be . PMID: 28278336
48. findings suggest that in Hodgkin's lymphoma patients, HLA-A*29 allele might be a presumptive predisposing factor. PMID: 27063556
49. We found that the HLA-A*02-B*46 haplotype might be a prognostic marker in addition to the traditional TNM staging in patients with We found that the HLA-A*02-B*46 haplotype might be a prognostic marker in addition to the traditional TNM staging in patients with NPC. PMID: 27752910
50. we report genomic full-length sequence of a novel HLA-A*11:01:01:02 allele identified in a Chinese individual. HLA-A*11:01:01:02 has three nucleotide differences from HLA-A*11:01:01:01 PMID: 27079157
顯示更多

收起更多
亞細胞定位：

Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein.
蛋白家族：

MHC class I family
組織特異性：

Ubiquitous.
數據庫鏈接：

HGNC: 4931

OMIM: 142800

STRING: 9606.ENSP00000366005

UniGene: Hs.181244